In this interactive session, Life Sciences CEOs will explain what their concerns are while evaluating opportunities outside their organizations and maximizing the opportunities inside their organizations. Topics will include:
- How does a CEO incorporate shareholder valuation into the due diligence process?
- How do you measure acceptable risk?
- What due diligence factors do you use in selecting a partner for a collaboration agreement?
Panelists include: George Daniloff, CEO, Carbylan BioSurgery; Dinesh V. Patel, Ph.D., President and CEO, Arête Therapeutics; Tom Moran, Of Counsel, Foley; Jay Sheppard, President and Chief Executive Officer, Relypsa, Inc.; and James A. D. Smith, President and Chief Executive Officer, Genelabs.
Related Insights
June 20, 2025
Foley Viewpoints
Federal Court Enjoins Former Franchisees and Two Related Entities from Competing Against Franchisor
A federal court recently granted in part and denied in part a franchisor’s motion to enjoin the post-termination activities of its former…
June 20, 2025
Foley Viewpoints
Benefits Basics – When an Employee Becomes Disabled: A Resource Guide for HR & Benefits Professionals
Explore key considerations and plan-by-plan guidance for HR and benefits professionals navigating compensation and benefits issues when an employee becomes disabled.
June 20, 2025
Foley Viewpoints
Tricky Compliance Issues for Companies When an Executive Terminates Employment: 409A Applicability to Severance
Understand the key differences between Section 409A exempt and compliant severance benefits, and how each impacts tax treatment, flexibility, and compliance obligations when executives terminate employment.